Figure 3 | Blood Cancer Journal

Figure 3

From: CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

Figure 3

Profile of recovery NK cells in remission AML. PB was drawn from 5 HDs and 20 AML remission patients for NK phenotype analysis by flow cytometry. (a) Compared with HDs (circles), NK cells accounted for the similar percentage of lymphocytes in the PB of AML patients in remission (squares). (b) The CD16+ NK cells (ADCC functional NK cells) of patients were also comparable in frequency to that of HDs. (c) However, the intensity of CD16 expression on NK cells in remission AML was statistically lower than that in HD. (d) The percentage of CD56bright immature NK cells was higher in remission patients than that in HDs.

Back to article page